9301 Amberglen Blvd. Ste 100
About Molecular Templates
Molecular Templates (MTEM) is a clinical stage biopharmaceutical company focused on the development of a next generation immunotoxin platform technology called Engineered Toxin Bodies (ETB) in oncology. MTEM’s lead program, MT-3724, is in clinical development for non-Hodgkin’s lymphoma and additional pipeline drug candidates are being advanced toward clinical development for a variety of cancers. For more information, please visit MTEM’s website at www.mtem.com.
STOCK SYMBOL: MTEM
STOCK EXCHANGE: NASDAQ
24 articles with Molecular Templates
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
9/20/2018Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals.
A look at the past year and what's in store for Molecular Templates in 2018.
Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer
Mr. Cutler will report to the CEO and will be responsible for all corporate finance, accounting, and investor relations activities.
Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)
Takeda And Molecular Templates Announce Multi-Target Research And Licensing Collaboration To Develop Next-Generation Oncology Therapies
Molecular Templates Inc. To Present Clinical And Preclinical Data For MT-3724 And Next Generation Engineered Toxin Bodies (ETBS) At The 2016 AACR Annual Meeting
Molecular Templates Inc. Presents Preclinical Data On De-Immunized Engineered Toxin Bodies (ETB) With Novel Immuno-Oncology Capabilities At The 2015 American Association for Cancer Research Annual Meeting
Molecular Templates Inc. Announces Start Of Phase 1 Clinical Trial Of MT-3724 In Refractory Non-Hodgkin’s Lymphoma
Veristat, Inc. And Molecular Templates Inc. Enter Into Preferred Provider Agreement For Refractory Non-Hodgkin’s B-Cell Lymphoma trial
Molecular Templates Inc. Presents Preclinical Data On CD38-Targeted Engineered Toxin Body (ETB) At The American Association For Cancer Research Special Conference, Hematologic Malignancies: Translating Discoveries To Novel Therapies
Molecular Templates Inc. Templates Announces FDA Approval Of Investigational New Drug Application For CD20 Internalizing Immunotoxin MT-3724
Molecular Templates Inc. Presents Preclinical Data On Engineered Toxin Bodies (ETBs) At The American Association for Cancer Research Annual Meeting
Molecular Templates Inc. to Present at 2013 Biotechnology Industry Organization (BIO) International Convention
Molecular Templates Inc. Announces RNAi Drug-Delivery Research Collaboration with Alnylam Pharmaceuticals